CNBC
29 May 2026, 03:10 UTC · 16h ago
Source · https://www.cnbc.com/2026/05/29/innovent-shares-rise-10percent-after-pact-with-pfizer-of-up-to-10point5-billion.html
Read source
Story key points
4 claims · impact-rated
Innovent Biologics entered into a partnership with Pfizer for the development of 12 early-stage oncology medicines with a total potential deal value of up to $10.5 billion. — A multi-billion dollar deal with a global leader like Pfizer provides massive capital infusion and validates Innovent's drug pipeline.
+0.80Innovent will receive an immediate upfront payment of $650 million from Pfizer. — Guaranteed immediate cash flow significantly strengthens the company's balance sheet and reduces near-term funding risk.
+0.60Innovent and Pfizer will co-commercialize the developed products in the U.S. and Europe and share profits. — Gaining access to the high-value U.S. and European markets via Pfizer's infrastructure dramatically increases the potential revenue ceiling.
+0.50Continue reading
6 related stories
Search tags
Innovent retains the rights to these oncology programs within the Greater China market. — Preserving domestic rights ensures the company maintains a strong hold on its primary home market while expanding globally.
+0.30Ticker attribution
Model heads
Shares rose 10% following a strategic deal with Pfizer worth up to $10.5 billion.
The company is proactively addressing pipeline gaps through a strategic oncology partnership.
Impact vectors
12 dimensions · 9 clusters
Market reaction
10 bid · 1 offered
Business Wire
9h ago
